Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker

AIM: SGLT2 inhibitors provide multiple benefits to patients with type 2 diabetes – including improved glycemic control and decreased risks of cardiorenal disease. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Simeon I., Cherng, Hua-Ren, Yazdi, Zhinous Shahidzadeh, Montasser, May E., Whitlatch, Hilary B., Mitchell, Braxton D., Shuldiner, Alan R., Streeten, Elizabeth A., Beitelshees, Amber L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029014/
https://www.ncbi.nlm.nih.gov/pubmed/36945579
http://dx.doi.org/10.1101/2023.03.07.23286875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029014/
https://www.ncbi.nlm.nih.gov/pubmed/36945579
http://dx.doi.org/10.1101/2023.03.07.23286875

Ejemplares similares